News
Hosted on MSN11mon
Amgen's peek at its GLP-1 drug trial results heightens competition in obesity marketAmgen's (AMGN) positive trial results update on its GLP-1 injectable for obesity, MariTide, sent its stock up more than 13% in trading Friday. CEO Bob Bradway shared a peek at phase II results of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback